Table 3.
Studies assessing the prognostic value of T cells and B cells in OSCC
| Authors, ref. | Number of patients, tumour size/stage, Inclusion period, country | Tumour compartment analysed | Direction of effect on survival high cell count | Statistical significance | |
|---|---|---|---|---|---|
| UV | MV | ||||
| T cells | |||||
| Marker: CD3, pan T cell marker | |||||
| Wirsing et al.28 | 74, T1–T4, 1986–2002, Norway | Stroma at tumour front | Positive | DSS: P = 0.200 | NA |
| Ahn et al.23 | 68a, Stage I–IV, 2003–2011, South Korea | Stroma | Positive | OS: P = 0.142, HR 0.99 (95% CI 0.98–1.00) | NA |
| No effect | DFS: P = 0.552, HR 1.00 (95% CI 0.98–1.01) | NA | |||
| Sakakura et al.45 | 74, Stage I–IV, 2000–2012, Japan | Tumour periphery | No info | OS: P = 0.856, PFS: P = 0.981 | NA |
| Dayan et al.34 | 54, Stage I–IV, 1990–2006, Israel | Tumour–stroma interface | No info | OS: P > 0.05 | NA |
| Marker: CD4, various T cell subsets | |||||
| Wirsing et al.28 | 72, T1–T4, 1986–2002, Norway | Stroma at tumour front | Positive | DSS: P = 0.691 | NA |
| Fang et al.29 | 78a, Stage I–IV, 2007–2009, China | Stroma | No info | OS: P = 0.207, HR 1.458 (95% CI 0.812–2.618)b | OS: P = 0.909, HR 0.963 (95% CI 0.506–12.835)b |
| Mattox et al.47 | 47a, T1/T2, N0–N2, Period missing, US | No info | Positive | OS: P = 0.18 | NA |
| Dayan et al.34 | 54, Stage I–IV, 1990–2006, Israel | Tumour–stroma interface | No info | OS: P > 0.05 | NA |
| Cho et al.46 | 45, Stage I–IV, Period missing, South Korea | Peritumour | Positive | OS: P = 0.571 | NA |
| Watanabe et al.48 | 87, Stage I–IV (M0), 1994–2003, Japan | Stroma | No info | OS: P = 0.072 | NA |
| Nest | No info | No info | NA | ||
| Marker: T-bet, Th1 cell marker | |||||
| Fang et al.29 | 78a, Stage I–IV, 2007–2009, China | Stroma | No info | OS: P = 0.639 h 1.148 (95% CI 0.645–2.045)b | OS: P = 0.836, HR 0.938 (95% CI 0.510–1.724)b |
| Marker: FoxP3+/− CCR4, Treg marker | |||||
| Ahn et al.23 | 68a, Stage I–IV, 2003–2011, South Korea | Stroma | Positive | OS: P = 0.374, HR 0.98 (95% CI 0.93–1.03) | NA |
| Negative | DFS: P = 0.754, HR 1.01 (95% CI 0.96–1.06) | NA | |||
| Zhou et al.49 | 46, Stage I–IV, 2006–2011, China | Stroma | Negative | OS: P = 0.001 | OS: P = 0.021, RR 15.152 (CI no info)b |
| Fujita et al.40 | 50a, Stage I–IV, 2006–2010, Japan | Invasive front | No info | OS: P > 0.05, DSS: P > 0.05 | NA |
| Intratumour | No info | OS: P > 0.05, DSS: P > 0.05 | NA | ||
| Dayan et al.34 | 54, Stage I–IV, 1990–2006, Israel | Tumour–stroma interface | No info | OS: P > 0.05 | NA |
| Watanabe et al.48 | 87, Stage I–IV (M0), 1994–2003, Japan | Stroma | Negative | OS: P = 0.31 (FoxP3) | No info |
| OS: P = 0.001 (FoxP3/CCR4+) | No info | ||||
| Marker: CD8, cytotoxic T cell marker | |||||
| Wirsing et al.28 | 72, T1–T4, 1986–2002, Norway | Stroma at tumour front | Negative | DSS: P = 0.304 | NA |
| Ahn et al.23 | 68a, Stage I–IV, 2003–2011, South Korea | Stroma | Positive | OS: P = 0.181, HR 0.99 (95% CI 0.97–1.01) | NA |
| Positive | DFS: P = 0.282, HR 0.99 (95% CI 0.96–1.01) | NA | |||
| Fang et al.29 | 78a, Stage I–IV, 2007–2009, China | Stroma | Positive | OS: P < 0.001, HR 0.263 (95% CI 0.138–0.501)b | OS: P = 0.030, HR 0.460 (95% CI 0.228–0.928)b |
| Kogashiwa et al.50 | 84, Stage III–IVA, 2007–2014, Japan | No info | Positive | OS: P = 0.058 | NA |
| PFS: P = 0.35 | |||||
| Mattox et al.47 | 48a, T1/T2, N0–N2, Period missing, US | No info | No info | OS: P = 0.41 | NA |
| Wu et al.51 | 165, T1–T4, 2008–2010 and 2012–2015, China | No info (TMA) | Positive | OS: P = 0.0498 | OS: P = 0.052, HR 0.579 (95% CI 0.333–1.005) |
| Dayan et al.34 | 54, Stage I–IV, 1990–2006, Israel | Tumour–stroma interface | No info | OS: P > 0.05 | NA |
| Cho et al.46 | 44, Stage I–IV, Period missing, South Korea | Intratumour | No info | No info | NA |
| Peritumour | Positive | OS: P = 0.178 | NA | ||
| Watanabe et al.48 | 87, Stage I–IV, M0, 1994–2003, Japan | Stroma | Positive | OS: P = 0.001 | NA |
| Nest | Positive | OS: P = 0.001 | NA | ||
| Zancope et al.44 | 40, T1–T4, Period missing, Brazil | Peritumour | Positive | OS: P = 0.40 | NA |
| Intratumour | No info | OS: P = 0.9 | NA | ||
| B cells | |||||
| Marker: CD20, pan B-cell marker | |||||
| Wirsing et al.28 | 75, T1–T4, 1986–2002, Norway | Stroma at invasive front | Positive | DSS: P = 0.002 | DSS: P > 0.05 |
| Ahn et al.23 | 68a, Stage I–IV, 2003–2011, South Korea | Stroma | Positive | OS: P = 0.186, HR 0.98 (95% CI 0.96–1.00) | NA |
| Positive | DFS: P = 0.496, HR 0.99 (95% CI 0.97–1.02) | NA | |||
| Dayan et al.34 | 54, Stage II–V, 1990–2006, Israel | Tumour–stroma interface | No info | OS: P > 0.05 | NA |
| Marker: CD19, pan B-cell marker | |||||
| Lao et al.52 | 93a, Stage I–IV, Period missing, China | Stroma | Positive | OS: P = 0.008 | OS: Significant, but P-value and HR missing |
| Marker: CD138, plasmacell marker | |||||
| Dayan et al.34 | 64, Stage I–IV, 1990–2006, Israel | Tumour–stroma interface | No info | OS: P > 0.05 | NA |
| Marker: IL19/CD19, Breg marker | |||||
| Zhou et al.49 | 46, Stage I–IV, 2006-2011, China | Stroma | Negative | OS: P = 0.001 | OS: P = 0.528, RR 1.575 (CI no info)b |
OS overall survival, if survival was not specified it was interpreted as overall survival, DSS disease-specific survival, PFS progression-free survival, HR hazards ratio, RR risk ratio, NA not applied
Significant values are bold (p< 0.05)
aDenotes that information about chemotherapy/radiation exposure of tissue prior to surgery was missing or ambiguous
bDenotes that the HR and CI were inverted in these studies